Tacrolimus and cyclosporine are the most used options in clinical practice for maintenance therapy. In this study, we performed a cost-effectiveness analysis of tacrolimus versus cyclosporine, evaluating the cost-effective therapeutic scheme in the Colombian context, considering organ rejection avoided as a clinical outcome. The result of this research shows the economic and clinical benefits of the use of both therapeutic schemes, tacrolimus only achieves cost-effectiveness in 1 treatment regimen, being above the cost-effectiveness threshold in the remaining regimen.